-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 MorR3h249fljevL2ag8X2/x6WTsZVN1qSil0lVKqumUOpHiZs+QFMN65Vf1clU2a
 Z2MRopjgZbm/i8Bv7Q+1NQ==

<SEC-DOCUMENT>0001140361-09-009395.txt : 20090410
<SEC-HEADER>0001140361-09-009395.hdr.sgml : 20090410
<ACCEPTANCE-DATETIME>20090410091056
ACCESSION NUMBER:		0001140361-09-009395
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20090410
DATE AS OF CHANGE:		20090410
EFFECTIVENESS DATE:		20090410

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ORTHOLOGIC CORP
		CENTRAL INDEX KEY:			0000887151
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				860585310
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33560
		FILM NUMBER:		09744143

	BUSINESS ADDRESS:	
		STREET 1:		1275 WEST WASHINGTON STREET
		CITY:			TEMPE
		STATE:			AZ
		ZIP:			85281
		BUSINESS PHONE:		6024375520

	MAIL ADDRESS:	
		STREET 1:		1275 WEST WASHINGTON STREET
		CITY:			TEMPE
		STATE:			AZ
		ZIP:			85281
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>formdefa14a.htm
<DESCRIPTION>ORTHOLOGIC CORP DEFA 14A 4-10-2009
<TEXT>
<html>
  <head>
    <title>formdefa14a.htm</title>
<!-- Licensed to: EDGARfilings, Ltd.-->
<!-- Document Created using EDGARizer 4.0.7.0 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div>
      <div>
        <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
        <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">UNITED
STATES</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">SECURITIES
AND EXCHANGE COMMISSION</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">Washington,
D.C.&#160;&#160;20549</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">______________________</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">SCHEDULE
14A</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PROXY
STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXCHANGE
ACT OF 1934</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Filed by
the Registrant <font style="DISPLAY: inline;" face="Wingdings 2, serif">T</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Filed by
a party other than the Registrant <font style="DISPLAY: inline;" face="Wingdings 2, serif">&#163;</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Check the
appropriate box:</font></div>
      <div>
        <div align="left">
          <table cellpadding="0" cellspacing="0" width="100%">
              <tr>
                <td valign="top" width="5%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings 2, serif">&#163;</font></div>
                </td>
                <td valign="top" width="95%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Preliminary
      proxy statement.</font></div>
                </td>
              </tr>
              <tr>
                <td valign="top" width="5%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings 2, serif">&#163;</font></div>
                </td>
                <td valign="top" width="95%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Confidential,
      for use of the Commission only (as permitted by Rule
      14a-6(e)(2)).</font></div>
                </td>
              </tr>
              <tr>
                <td valign="top" width="5%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">

                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings 2, serif">&#163;</font></div>
                  </div>
                </td>
                <td valign="top" width="95%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Definitive
      proxy statement.</font></div>
                </td>
              </tr>
              <tr>
                <td valign="top" width="5%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">

                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings 2, serif">T</font></div>
                  </div>
                </td>
                <td valign="top" width="95%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Definitive
      additional materials.</font></div>
                </td>
              </tr>
              <tr>
                <td valign="top" width="5%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings 2, serif">&#163;</font></div>
                </td>
                <td valign="top" width="95%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Soliciting
      material pursuant to
&#167;240.14a-12.</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <div align="center">
          <table cellpadding="0" cellspacing="0" width="100%">
              <tr>
                <td valign="top" width="100%" style="BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 24pt; FONT-FAMILY: times new roman">ORTHOLOGIC
      CORP.</font></div>
                </td>
              </tr>
              <tr>
                <td valign="top" width="100%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Name
      of Registrant as Specified in Its Charter)</font></div>
                </td>
              </tr>
              <tr>
                <td valign="top" width="100%" style="BORDER-BOTTOM: black 2px solid">
                  <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></div>
                  <div>&#160;</div>
                </td>
              </tr>
              <tr>
                <td valign="top" width="100%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Name
      of Person(s) Filing Proxy Statement, if other than the
      Registrant)</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <div align="center">
          <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
              <tr valign="top">
                <td>
                  <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Payment
      of filing fee (check the appropriate
box):</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div>
        <div align="left">
          <table cellpadding="0" cellspacing="0" width="100%">
              <tr>
                <td align="left" valign="top" width="5%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings 2, serif">T</font></div>
                </td>
                <td align="left" valign="top" width="95%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">No
      fee required.</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="5%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings 2, serif">&#163;</font></div>
                </td>
                <td align="left" valign="top" width="95%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fee
      computed on table below per Exchange Act Rules 14a-6(i)(1) and
      0-11.</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <div align="left">
          <div align="left">
            <div align="left">
              <div align="left">
                <div align="left">
                  <table cellpadding="0" cellspacing="0" width="100%">
                      <tr>
                        <td align="left" valign="top" width="5%" style="PADDING-BOTTOM: 2px">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1)</font></div>
                        </td>
                        <td align="left" valign="top" width="40%" style="PADDING-BOTTOM: 2px">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title
      of each class of securities to which transaction applies:</font></div>
                        </td>
                        <td valign="top" width="55%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" width="5%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                        <td align="left" valign="top" width="40%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px">
                          <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
                        </td>
                        <td valign="top" width="55%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      </tr>
                  </table>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div>
        <div align="left">
          <table cellpadding="0" cellspacing="0" width="100%">
              <tr>
                <td align="left" valign="top" width="5%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2)</font></div>
                </td>
                <td align="left" valign="top" width="95%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Aggregate
      number of securities to which transaction applies:</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="5%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                </td>
                <td align="left" valign="top" width="95%" style="BORDER-BOTTOM: black 2px solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <div align="left">
          <div align="left">
            <table cellpadding="0" cellspacing="0" width="100%">
                <tr>
                  <td align="left" valign="top" width="5%" style="PADDING-BOTTOM: 2px">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3)</font></div>
                  </td>
                  <td align="left" valign="top" width="70%" style="PADDING-BOTTOM: 2px">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Per
      unit price or other underlying value of transaction computed pursuant to
      Exchange Act Rule 0-11 (set forth the amount on which the filing fee is
      calculated and state how it was determined):</font></div>
                  </td>
                  <td valign="top" width="25%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                </tr>
            </table>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <div align="left">
          <div align="left">
            <div align="left">
              <div align="left">
                <div align="left">
                  <div align="left">
                    <table cellpadding="0" cellspacing="0" width="100%">
                        <tr>
                          <td align="left" valign="top" width="5%" style="PADDING-BOTTOM: 2px">
                            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4)</font></div>
                          </td>
                          <td align="left" valign="top" width="35%" style="PADDING-BOTTOM: 2px">
                            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Proposed
      maximum aggregate value of transaction:</font></div>
                          </td>
                          <td valign="top" width="60%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" width="5%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                          <td align="left" valign="top" width="35%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px">
                            <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
                          </td>
                          <td valign="top" width="60%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                        </tr>
                    </table>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div>
        <div align="left">
          <div align="left">
            <table cellpadding="0" cellspacing="0" width="100%">
                <tr>
                  <td align="left" valign="top" width="5%" style="PADDING-BOTTOM: 2px">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5)</font></div>
                  </td>
                  <td align="left" valign="top" width="20%" style="PADDING-BOTTOM: 2px">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total
      fee paid:</font></div>
                  </td>
                  <td valign="top" width="75%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                </tr>
            </table>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <div align="left">
          <table cellpadding="0" cellspacing="0" width="100%">
              <tr>
                <td align="left" valign="top" width="5%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings 2, serif">&#163;</font></div>
                </td>
                <td align="left" valign="top" width="95%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fee
      paid previously with preliminary materials.</font></div>
                </td>
              </tr>
              <tr>
                <td align="left" valign="top" width="5%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings 2, serif">&#163;</font></div>
                </td>
                <td align="left" valign="top" width="95%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Check
      box if any part of the fee is offset as provided by Exchange Act Rule
      0-11(a)(2) and identify the filing for which the offsetting fee was paid
      previously.&#160;&#160;Identify the previous filing by registration
      statement number, or the form or schedule and the date of its
      filing.</font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <div align="left">
          <div align="left">
            <table cellpadding="0" cellspacing="0" width="100%">
                <tr>
                  <td align="left" valign="top" width="5%" style="PADDING-BOTTOM: 2px">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1)</font></div>
                  </td>
                  <td align="left" valign="top" width="25%" style="PADDING-BOTTOM: 2px">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Amount
      Previously Paid:</font></div>
                  </td>
                  <td valign="top" width="70%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                </tr>
            </table>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <div align="left">
          <div align="left">
            <div align="left">
              <div align="left">
                <div align="left">
                  <table cellpadding="0" cellspacing="0" width="100%">
                      <tr>
                        <td align="left" valign="top" width="5%" style="PADDING-BOTTOM: 2px">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2)</font></div>
                        </td>
                        <td align="left" valign="top" width="30%" style="PADDING-BOTTOM: 2px">
                          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form,
      Schedule or Registration Statement No.:</font></div>
                        </td>
                        <td valign="top" width="65%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" width="5%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                        <td align="left" valign="top" width="30%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px">
                          <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
                        </td>
                        <td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                      </tr>
                  </table>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div>
        <div align="left">
          <div align="left">
            <table cellpadding="0" cellspacing="0" width="100%">
                <tr>
                  <td align="left" valign="top" width="5%" style="PADDING-BOTTOM: 2px">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3)</font></div>
                  </td>
                  <td align="left" valign="top" width="20%" style="PADDING-BOTTOM: 2px">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Filing
      Party:</font></div>
                  </td>
                  <td valign="top" width="75%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                </tr>
            </table>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <div align="left">
          <div align="left">
            <table cellpadding="0" cellspacing="0" width="100%">
                <tr>
                  <td align="left" valign="top" width="5%" style="PADDING-BOTTOM: 2px">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4)</font></div>
                  </td>
                  <td align="left" valign="top" width="20%" style="PADDING-BOTTOM: 2px">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date
      Filed:</font></div>
                  </td>
                  <td valign="top" width="75%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                </tr>
            </table>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On April
10, 2009, OrthoLogic Corp. issued the following letter to stockholders. The
letter is posted on the Company<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8217;</font>s website at
www.capstonethx.com.</font></div>
      </div>
      <div>&#160;</div>
      <div>
        <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
        <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
      </div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div>
    </div>
    <div>&#160;</div>
    <div><img src="logo.jpg" alt=""></div>
    <div>&#160;</div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dear
Fellow Stockholders:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We are
pleased to present the enclosed OrthoLogic Corp. Proxy Statement for the Annual
Meeting of Stockholders.&#160;&#160;On October 1, 2008, OrthoLogic Corp. began
doing business under the trade name of Capstone Therapeutics.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
outlined most recently during our Investor Teleconference and Webcast on
February 10, 2009, the Capstone Therapeutics team achieved every corporate
objective for 2008 as established by the company&#8217;s Board of
Directors.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
AZX100, we had a successful dermal scarring Phase 1a safety study (30 subjects)
in which the primary safety endpoint was met.&#160;&#160;We also completed a
Phase 1b safety study in dermal scarring (40 subjects) in which the product
again met the primary safety endpoint.&#160;&#160;This study also yielded
results showing a significant pharmacologic effect of AZX100, with a trend of
efficacy in scar reduction.&#160;&#160;The Phase 2 program in dermal scarring is
underway; as previously announced, Capstone anticipates a year-end 2009 interim
analysis for internal purposes, with full results during 2H2010.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
recently announced initiation of our AZX100 Phase 2 pilot clinical trial in
keloid scarring, a dermal indication which represents a challenging and
widespread unmet medical need.&#160;&#160;We anticipate conducting an internal
observational analysis at year-end 2009, with data expected during
2H2010.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During
2008, the team continued to make progress on several pre-clinical studies in
other high-value indications for AZX100.&#160;&#160;We also completed and
announced the publication of data describing a key aspect of the AZX100
mechanism of action in dermal fibroblasts; these data provided the scientific
rationale for initiating our ongoing clinical trial program in dermal
scarring.&#160;&#160;Capstone believes that AZX100 has potential application in
multiple therapeutic indications.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
Chrysalin<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">&#174;</font> (TP508),
Capstone completed a landmark pre-clinical proof-of-concept study showing
significant cardioprotective benefit in a model of acute myocardial infarction
(heart attack).&#160;&#160;The first publication of these data was announced on
March 5, 2009.&#160;&#160;We also published during 2008 several key studies on
cellular effects and mechanism of action of TP508.&#160;&#160;As promised, we
initiated a corporate partnering process for TP508 in the cardiovascular
indication, and this effort is ongoing.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Capstone
closed 2008 with $48.0 million in cash and investments, favorable to the
guidance provided at the beginning of the year.&#160;&#160;We continue to manage
our assets with discipline, and remain focused on driving all programs toward
value events for our stockholders as effectively and efficiently as
possible.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
appreciate your voting support of the proxy recommendations of the Capstone
Therapeutics Board of Directors.&#160;&#160;As we continue to tighten the cost
structure of the company to optimize our cash resources in clinical development,
the Board has proposed a small incremental pool of stock options to incentivize
our team.&#160;&#160;The recommendation for 1,250,000 shares is well within
guidelines supported by our independent shareholder services analysts, and we
expect these additional shares available for grant will be sufficient for the
Company&#8217;s stock-based incentive compensation requirements through
2011.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Thank you
for your continuing support.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Sincerely,</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">/s/ John M. Holliman, III</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">John M.
Holliman, III</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Executive
Chairman</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">April
2009</font></div>
    <div>&#160;</div>
    <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font>

      <div>
        <hr style="COLOR: black" align="left" noshade size="2" width="100%">
      </div>
    </div>
  </body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``8$!08%!`8&!08'!P8("A`*"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!#`0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P``1"`!)`*P#`2(``A$!`Q$!_\0`
M'0```00#`0$`````````````"``%!@<!!`D#`O_$`$D0``$#`P$#!PD$!@<)
M`0````$"`P0`!081$B$Q!P@3%$%1<148(C)68724T2,SD;(6-39"@:$D4E-B
M9'*$)30W1E1S@K&SX?_$`!4!`0$````````````````````!_\0`&!$!`0$!
M`0```````````````!$!(4'_V@`,`P$``A$#$0`_`"&SW,;7A&/NW:\N*#23
ML-M(&JW5G@E([ZH5_G02.F7U?&$]%KZ.W)]+3WZ"L<\=]WRAC,;;/0AMYS8[
M-K5(U_"ASHN8(KSGYOLRS\P?I2\Y^;[,L_,'Z4.M*BP17G/S?9EGY@_2EYS\
MWV99^8/TH=:5""*\Y^;[,L_,'Z4O.?F^S+/S!^E#K2H017G/S?9EGY@_2EYS
M\WV99^8/TH=1J5!(!*B=``-2:L''.3"X2X2;IDTIK'[+QZ:5N=<'<A''6B<6
M4CG/3UK"&\6;6L\$I?)/X`5\CG033_RRS\P?I3QBF-6^T6A4BPPHMCMBQL*O
ME\2.FD$_V;9W@'O.FZHGGV"PD.!=_B)M+SWW-W@^G"D:\"K3U2??I0.OG/S?
M9EGY@_2EYS\WV99^8/TJELEP^[8^.ED,B1"5O1+C^FVH=^HX5'0=>%%$7YS\
MWV99^8/TI><_-]F6?F#]*'6E0@BO.?F^S+/S!^E+SGYOLRS\P?I0ZTJ$$5YS
M\WV99^8/TI><_-]F6?F#]*'6E0@L,"YQ4"^WR-;+Y:EVU4IQ+3,A#FVC;)T`
M5VC4]M7U7-7;4T0XV2E:#M)(["-X-=&L>>7(L%M>=.KCD9M:CWDI&M$T-O/&
M_76,_#O?F30[T1'/&_76,_#O?F30[T7"I5Z1V'I+G1Q6'7W!OV6D%1_`5\O-
MN,.]%(:<:<_J.)*3^!H/FE2KZ<;6TLH=;6VL<4K201_`T'P2!QJ;8IR<7F^1
MO*$PM6>RIWKG3CL)T_N@[S6GA-Z\BNJDQL98O$Q!]%UY"G`UW>B!I^-;%XRV
M\W&\LS\SAO7**@_9P)`4Q'U[!H.P=U#JR\&M=O;D*C\F-D\LS6]S^171.S%8
M[R@'C_"GA$ZW1<A#%N+G*!G*3Z4E[=`MY[P/5`'NWU5.5\IV0Y1#9L\)INU6
MA"0E-NMB2D+`[R-YIXQ7E0N.,PF[18\1AQ^]&ROI73IJ2K=J3VU4B\8^//J;
M>N>4S?+%Y+:@%*3HQ'!&]+3?`#W\347'EG'6G58UT4ZV.:]8L4WTF7`>/1D^
MH?=PJ$/\N&2.,+0K'&$I4-DG87N_E3:URHY$ZXEMK'DK6>`#:]3_`"IQ)J:6
MB/:\@<?/)U.\CW=.IE8M=_NEGM#>O#^&ZH-?\=LTZY+@7&*[B.2?]/(']'>/
M>A7#0^ZHSE6:+R%3;[]LC19[)U;F1UJ2XG3W]M2)OE*OMUQ;R5E&/LY-"2/L
MI4EE0=;'N<2.SOJ+$*R+&KKCSVS<XJDM'U'T>DVL=X4*9ZDUCS:YVE#D9&Q,
MMBB084O[1`'<"=XIJNZNMK,Z-:50(JSI]F%%K7W$\/"BFZE2KWZE+Z)#O5)'
M1+.B5]&=E1]Q[:#PI5NBTW,\+9/.G^'7]*\Y%OFQD;<J%*81PVG65)'XD4&H
MY]VKPKHQBO[,VGX1K\@KG.Y]VKPKHQBO[,VGX1K\@HFAQYXWZZQGX=[\R:I7
M!<9DY?E$*S1%AKIB5//'@RTG>M9\!5U<\;]=8S\.]^9-1;D0;$+#.46^(`ZS
M'MW5FU=J=L'73^5#Q%<JRWJ\IVT88I5KL$51;;4SN>E$;BZXOB23O`X`4XX9
MG[Q;EVO*TL72([&=3%DRFPIV*]L'9*5\=">RJW1ZB?"OJBG#&8R95VB(>&K3
M?VSNO]5`VC^.FG\:GW+847IO&,QCMI0W>H`2^$C0)?:]%0_#3\*BN+-0F[5>
M)=SE.Q&G$)AM.--=(=I1VE#34?NI'XU-XK-MO?(C>K7:YK\Z38)2;FWTK'1J
M2TOT5@;SJ.)H-'F]/NMYY);;<4EM=KEE20=Q(;)'X&L\A\MV^9BG&+TM<ZSW
M=IUIUEX[6PH)*DN))]50(XUY\WHI'*&Z5`E/DN7J`=-1T9J/67*V<<$I[&[<
MJ-<GVEL==D/=(ME"MRNC```)&[6@?+G;UXUR6PI]J60[<+I(C2IJ/62AK<AL
M*_=!WJ]^ZF6!G=XBM6@+>+TBU/N/17W`"M&V@IT)[0-=1K6YR>Y\K&8LJT7>
MWM7K&IJMJ3!>XA7]=![%5L<HF(V>%9H.4X9,<DXW/<+/1/?>Q'>);5WT#WR&
M9'>KGRJVIJY725*9=#REMNJVDJ/1J.\>-1&#G>1VN].2$7:4ZA*W$+:<5JE:
M#J"DBGGF]_\`%NR_Y7__`)*JOY?^^2/^ZK_V:";XM9XEGPB;FMVC(E'K'4K3
M$=&K:WN*G5CM2D=G::C#V1WMZ7UE=UE![74%"]D)\`-P'NJ?Y,I,OF[X@N-O
M1#N3[,C3]U9U(U\:JN@L-F"WG6$W:YI9;;R:Q)2](6TG9$Z,=Q4H#=MI/;VB
MO;DAR.%"C7FT905OXM.:0V^WQZ!2E:!Y/<1NK=Y!'41&<ZG2CI#9L;B7">!*
MCHD?C5=V<?["O(/]@U^>@W\]Q27AN2/VN6H.M:!V+)3ZLAD^JL'PX^^OB9<)
MBL)M<0R7>KM3'E(;VMR3H-XJ=89)9Y1<2&$W9U"+]`2IVQ2W#H5@#54=1[CV
M?_E0"Z1WHF/QHTMI;,AF:^VXVL:%"@`"#06KRN7RZHY-N362S<)++[\)9>6T
MO9+A`2`5:<:K)67WF1CLZRW"?(F0I*FW$I>5M=&M*M=0>S7A5G<H]CN=YY*^
M3/R7#7)Z*"O;V5)&SJ$Z<2*K*_8==[!88=SO$8Q4S'U-,ME25%02-2K<3IV"
M@C;GW:O"NC&*_LS:?A&OR"N<[GW:O"NC&*_LS:?A&OR"B:''GC?KK&?AWOS)
MJ,<@2TW.R9UC`5I(N-M+K">U:D`[A_*I7SQV'/*&,R-@]"6WF]KLVM4G3\*H
M?%[[.QF_PKQ:E[$N*O;3KP4.U)]Q&ZAX:@"D;*@0I.X@]A%9JR,BMF-9G.<O
M6-7B#9I<H])+M5Q46PVX?6+:P""DG?INJ-W"W6>Q1W`]<8UYN:TE*&H95T#'
M]Y2SIM'N`W45ZWR`B/C%DC0)2)CQ+DB6VTDZM.*.B1[]$@;Z?N1:9'LN3RSD
M#O5;--@O0Y6VDDJ2M.[0#CO`J)9,F`TNW"UA*0N&TZ_L.E>CI'I).O#3NIT;
MAV`X4J2M]7ESJZEA'2[MKI@D;M?6V-3I_&@D7)(FWXSG,Z3<[FTW;VXDB*T^
M$$]-TB=E)`\-YJNI-MDLR'6D-J>2E1`<;'HJ&O$4Z8G'MTHW3RN[L]'$*XVK
MFSJ[KN''?7AB;4*3?X[5Y=V(!"RZHK*0-$DC?X@4#Q(M-IN5DM/5)2X%W88+
M<QN2T0TZ=M1"DJ';H0"#7I=IG4\&CXM;0[,VIIN$N2E!2WM[.RE"`=Y`&\GM
MJ.9"U'CWR:S;7MN$'3T"@YM`H/J[_"MS)H<"(Q:W+5+Z4N,;$E(<U*7DG>?`
MZ[O"@DW(F]&L>?PKM?)'4845#FTI:"2LJ04@`#QJ&W2W/M7*4ED&2UTJBEUL
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MHE`*MY]Y(_A7Q?FXK`MOD]S4N0FW']EPJT=/K`]WA0:L9FX19+,B*W(9D,K#
MC;B!H4*!U!%3?E1R-G++38[D8)BWD)6FZ!*-$N.``)<_\@*C%X9A,6JWK@.(
M=4ZRE3KG2GI$N[]M!3V#AH:S`B0I6-35./)1=0^A+`<<]%Q!X@;]Q''4[M*"
MPN5TJ')9R7;*EI_H+GJJ([$]U54N?*7;4P''EKBH=Z9*%J)V5$:$C7W5<_*-
M;X%ZP#";9:LCL3T^SQRS*;7*V1JH#>DZ;]""*KN1BS%KL-PGW*\VEZ2A*6XL
M.)(Z5:U*(!4=!N"1J:&(BY]VKPKHQBO[,VGX1K\@KG3L*<]!`*EJ]%(':3P%
M=&L=97'L%M9=&RXW&;2H=Q"1K1-->?X;:\XQ]RTWE"NC)VVG4;ELK'!235"/
M<U^7TJ^AR=OHM?1VX^_3WT3]*B!<5S7IRO6R6.?&-61S7YP&@R9@#W1J**E1
M:%T<U^>.&3,?+5CS7IVNOZ3,:_#44=*A0N'FO3CQR9@^,:LGFOSSQR9@_P"F
MHHJ5"A='-?GCADS'RU8'-?G#ADS'RU%'2H4+OFOS]=?TF8U^&K!YKTXD$Y,Q
MJ/\`#44=*A0NGFOSB-#DS!\8U+S7YXX9,Q\M114J%"Z.:_/'#)F!_IJ0YK\\
M<,F8^6HHJ5"A=\U^=KK^DS&OPU8/->G'CDS'RU%'2H4+?FMS/:2-\K2'-=FI
M.J<EC@^Z-124J%4%@?-TA62^QKG?KLJY=5<2ZS';;V$%8.H*N_0Z'2K]I4J(
"_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
